Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q2 2020 Earnings Presentation
20 slides from Arcticzymes Technologies Asa's earnings presentation, 2020
Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: A new era - ArcticZymes Technologies
A new era - ArcticZymes Technologies Our Vision Our Mission With our daily work we want to make an As experts in our field, we discover, develop important contribution to a healthier world. and provide enzymes without compromises Driven by this goal, our experienced scientists on a consistently high
Slide 3: Agenda
Agenda 1 Highlights Q2 2020 2 ArcticZymes update 3 BetaGlucans update 4 Q2 Financials 5 Outlook
Slide 4: Highlights
Chapter 1 Highlights
Slide 5: Highlights Q2 2020
Highlights Q2 2020 Strong underlying growth with corona upsides ArcticZymes Group Q2 EBITDA Biotec Coronavirus NOK 27.2 mill. BetaGlucans related upsides (-0.5) operating in sales profitably ~NOK 11 mill. ArcticZymes Rebranded Q2 sales company to NOK 33.4 ArcticZymes mill.(9.0) Technologies 5
Slide 6: ArcticZymes update
Chapter 2 ArcticZymes update
Slide 7: ArcticZymes Update
ArcticZymes Update Commercial Achievements Key attributors to quarterly growth Therapeutics Covid-19 Upsides (Salt Active Nuclease) (Multiple enzymes) ✓34% contribution to total sales ✓33% contribution to total sales ✓Use extended into COVID-19 vaccine development ✓Served all commercial needs during
Slide 8: ArcticZymes Update
ArcticZymes Update Innovation Awarded 2 grants from Innovation Norway towards technology development to aid the fight against coronavirus Accelerate the upscaling of SAN production Accelerates ongoing efforts fits timely with foreseen commercial demand for coronavirus and non-coronavirus activities
Slide 9: BetaGlucans update
Chapter 3 BetaGlucans update
Slide 10: Biotec BetaGlucans
Biotec BetaGlucans Operating profitably Animal Health Consumer SBG® Woulgan® Health (Adjuvant) • Lower Q2 sales compared • Continued to achieved • Expedited 2nd SBG® order • Sales deliver to expectation to Q1 for M-Glucan® growth in M-Gard® sales relating to commitments • Discontinued Woulgan® suppo
Slide 11: Financials
Chapter 4 Financials
Slide 12: ArcticZymes Sales Q2 2020
ArcticZymes Sales Q2 2020 COVID-19 upsides represents one third of sales Sales per segment Sales growth of 270% 40 000 Amounts in NOK 1.000' Underlying business growth (excl. COVID-19 35 000 Therapeutics (SAN) upsides) of 150% 30 000 Research and Diagnostics COVID-19 (upsides) Therapeutics segment (
Slide 13: ArcticZymes Performance
ArcticZymes Performance Firing on all cylinders in Q2 Enzymes Q2 YTD Amounts in NOK 1.000' (Amounts in NOK 1.000) 2020 2019 2020 2019 40 000 Sales revenues 33 373 9 002 51 848 16 871 Sales Operating expenses -8 810 -7 658 -17 992 -16 543 35 000 EBITDA EBITDA 24 639 1 701 35 101 1 458 30 000 25 000 2
Slide 14: BetaGlucans Sales Q2 2020
BetaGlucans Sales Q2 2020 COVID-19 impacts demand for M-Gard Sales per segment Upsides in Consumer Health sales of M- Amounts in NOK 1.000' 18 000 Gard® related to COVID-19 16 000 Consumer Health Adjuvant Animal Health will continue to fluctuate 14 000 from quarter to quarter. Expects to be flat Wou
Slide 15: BetaGlucans Performance
BetaGlucans Performance Positive EBITDA for second straight quarter BetaGlucans Q2 YTD Amounts in NOK 1.000' (Amounts in NOK 1.000) 2020 2019 2020 2019 21 000 Sales revenues 10 947 7 851 26 745 14 798 Operating expenses -2 938 -5 140 -6 457 -11 660 EBITDA 16 000 EBITDA 4 178 -737 8 458 -2 846 Sales
Slide 16: ArcticZymes Technologies
ArcticZymes Technologies Sales growth in all the «right» areas Sales, Gross profit & EBITDA 50 000 Amounts in NOK 1.000' 40 000 Sales within high margin Sales segments secures solid gross Gross profit profit margin of 90% 30 000 EBITDA Enzymes segment is key contributor to growth in all 20 000 ratio
Slide 17: Changes in Cash
Cash Flow Dictated by underlying growth in the business Cash position Amounts in NOK 1.000' 60 000 25 000 20 000 50 000 15 000 40 000 Changes in Cash 10 000 Net Cash 56 109 30 000 5 000 35 667 20 000 31 300 28 190 22 056 - 21 369 10 000 -5 000 0 -10 000 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 202
Slide 18: Outlook
Chapter 5 Outlook
Slide 19: Outlook
Outlook Driving Strategic Growth & Profitability Profitability Expect to deliver number 1 goal in achieving profitability during 2020 New Opportunities Drive new opportunities that cement the foundation for 2021 and beyond Coronavirus Upsides Expect effect of Coronavirus upsides to be lower during t
Slide 20: Thank you!
Thank you! arcticzymes.com
ArcticZymes Technologies — Q2 2020 Earnings Presentation on 6ix